重组人血管内皮抑素联合化学治疗复治中晚期非小细胞肺癌临床观察

Clinical observations of Endostar combine with chemotherapy injection on advanced non-small cell lung cancer

目的观察重组人血管内皮抑素(恩度)联合化学治疗(化疗)注射液治疗复治中晚期(ⅢA、ⅢB、Ⅳ期)非小细胞肺癌(non small cell lung cancer,NSCLC)的临床疗效及不良反应。方法 32例经病理组织学或细胞学确诊的复治中晚期非小细胞肺癌患者,接受恩度注射液联合化疗治疗。15 mg恩度注射液中加入生理盐水500ml,匀速静脉滴注3～4 h,连续给药14 d。同时联合三代含铂化疗方案,21 d为1个周期。评价疗效及不良反应。结果 32例患者中,可评价近期疗效者30例,远期疗效者24例。可评价近期疗效的30例患者中,获得CR者0例,PR者15例,NC者11例,PD者4例;客观有效率为50%,临床获益率为86.67%。不良反应主要与化疗药物有关,也包括与恩度有关的心脏毒性。结论恩度注射液联合化疗治疗复治中晚期非小细胞肺癌,有效率得到一定程度提高,安全性好;但治疗过程中,应警惕心脏不良反应的发生。

Objective To observe the clinical effects of Endostar combined with chemotherapy injection in patients with advanced non-small cell lung cancer（NSCLC）.Methods Thirty-two patients with advanced non-small cell lung cancer who were definite by pathohistology or cytology,which received the treatment of Endostar combine with chemotherapy injection.Add Endostar injection 15mg into physiological saline 500 ml and vein intravenous drip brady-equally 3-4 hours for 14 days.Meanwhile,combining chemotherapeutic drugs that chemotherapy with platinum-based.Every 21 days is a periodicity to estimate efficacy and safety.Results Thirty patients displayed the to display curative effect and obtained that 0 CR,15 PR,11 SD and 4 PD,the objective response rate was 50% and disease control rate was 86.67%.The main toxicity is related to chemotherapeutics including cardiac toxicity related with Endostar.Conclusion Endostar combine with chemotherapy injection on advanced non-small cell lung cancer can improve efficacy with good safety.And we should give more attention during treatment with recombinant human endostatin combined with chemotherapy.